Promoting vascular repair in the retina: can stem/progenitor cells help?

Thao Le Phuong Trinh
Sergio Li Calzi
Lynn C Shaw
Mervin C Yoder
Maria B Grant

1Department of Ophthalmology, 2Department of Pediatrics, 3Herman B. Wells Center for Pediatric Research, 4Department of Biochemistry and Molecular Biology, Indiana University – Purdue University Indianapolis, Indianapolis, IN, USA

Abstract: Since its first epidemic in the 1940s, retinopathy of prematurity (ROP) has been a challenging illness in neonatology. Higher than physiological oxygen levels impede the development of the immature retinal neuropil and vasculature. Current treatment regimens include cryotherapy, laser photocoagulation, and anti-VEGF agents. Unfortunately, none of these approaches can rescue the normal retinal vasculature, and each has significant safety concerns. The limitations of these approaches have led to new efforts to understand the pathological characteristics in each phase of ROP and to find a safer and more effective therapeutic approach. In the era of stem cell biology and with the need for new treatments for ROP, this review discusses the possible future use of unique populations of proangiogenic cells for therapeutic revascularization of the preterm retina.

Keywords: retinopathy of prematurity, ROP therapy, endothelial progenitor cells, CD34+ cells, endothelial colony-forming cells, oxygen-induced retinopathy

Introduction

Retinopathy of prematurity (ROP) is a major cause of blindness in children worldwide.1,2 ROP causes approximately 14% of blindness in the US and more than 20% in developing countries.3 ROP only affects preterm newborns.4 Strikingly, the incidence of ROP has not changed significantly over the past 25 years, despite the fact that more resources have been devoted to the care of premature infants, such as pulse oximetry and surfactant antenatal steroids.1 ROP is associated with fluctuations in oxygen concentrations.4 The higher than physiological concentrations of oxygen that are needed to aid infant survival attenuate blood-vessel growth in the periphery, as well as the deep layers of the retina.5 Current treatments for ROP have targeted the more advanced stages, but none of the approaches is meant to resolve the underlying pathological defects, and inherently all current therapies carry adverse side effects. These therapies have been developed progressively with cryosurgery (1988) being developed first, then laser therapy (2003), and most recently intravitreal bevacizumab (2012).5

Mechanisms and current therapies for ROP

Mechanisms of vascular dysfunction

In order to understand the pathological events and how cell-based therapy works for ROP, the key features of normal retinal vasculature development need to be considered. Physiologic vasculogenesis of the retina begins in the posterior pole with the migration of precursor cells from the deep retina into inner layers, and is divided into different zones (Figure 1).1 Approximately between week 15 and
week 22 of gestation, these precursor cells differentiate into angioblasts, forming the inner vascular plexus, which will almost reach zone I.1 This transforming process is relatively independent of VEGF.1 However, after week 22, blood vessels are believed to grow and proliferate through a VEGF-dependent “budding” process and to some extent by angioblast transformation to vascularize peripheral zones II and III.1,4

Phase 1, or the vasocessation phase, begins with premature birth and supplemental oxygen given to premature infants at supraphysiological levels. The choroid is incapable of autoregulation, which results in the inner retina receiving excessive levels of oxygen. At this stage, the retinal outer segments, the most metabolically demanding cells in the body, have not appeared; therefore, the retina is under hyperoxia.1 The high oxygen concentration in turn downregulates hypoxia-induced VEGF, IGF-1, and CXCL-12 critical for normal vascularization.1,6,7 Diminished levels of vasogenic factors lead to delayed physiologic retinal vascular development, a key characteristic of the early phase of human ROP.4,8

Upon the return to ambient air, it is not clearly understood why one population of preterm infants do not develop intravitreal neovascularization (IVNV), also known as phase II or the neovascular phase of ROP, while the other group proceeds to abnormal neovascularization or serious ROP. However, it is appreciated that during this stage, the retina is likely to experience hypoxia, due to the tremendous rise in metabolism of the developing photoreceptor outer segments. Hypoxia itself can upregulate VEGF, which enhances angiogenesis and vasculogenesis.1

VEGF, formerly identified as “vascular permeability factor”, has increasingly been recognized to play a critical role in both physiologic as well as pathologic development of the vasculature, and is strongly associated with blood–retina barrier dysfunction.4,9 In fact, one of the prominent features of ROP is the breakdown of the blood–retina barrier. Edema caused by ischemia and vascular damage may be the direct culprit of neural cell depletion and immune-cell activation.10 We also know that VEGF signaling regulates ischemia-induced hyperpermeability, endothelial cell division, and morphology of branching vessels.11,12 To reemphasize the significant role of hypoxia-induced factors (HIFs), such as VEGF, studies in animal models of oxygen-induced retinopathy (OIR) support the view that severe ROP is linked to different exogenous factors, including oxygen levels, inflammation, and nutritional status, but all through dysregulated signaling cascades involving HIFs.4

**Current therapies and some reported pitfalls**

Cryosurgery, used in the multicenter CRYO-ROP trial, works by ablatting the avascular area of the peripheral retina to reduce the metabolic demand and the hypoxic level of retinal cells.1 Laser therapy was proved to be useful in the ET-ROP trial.1 The risk of poor prognosis in approximately 90% of eyes of severe ROP (or type 1 ROP), as in the ET-ROP study, may be lowered by laser treatment.4 However, generally ablation therapies tend to be costly, destructive, only reduce the risk of blindness by 25%, and may not prevent blindness particularly with zone I ROP.2,13 Laser photocoagulation was found to cause infectious ulcerative keratitis in a subgroup of ROP infants. The mechanism involved postoperative corneal epithelial defects that led to corneal haze.14 Another study of long-term ophthalmological outcomes in children treated for threshold ROP by indirect laser photocoagulation reported that these patients had higher risks of strabismus, astigmatism, nystagmus, myopia, and lowered visual acuity compared to the control subjects, infants with spontaneously regressed ROP.15

Most recently established (2012) is the use of anti-VEGF reagents like bevacizumab intravitreally. While injection of anti-VEGF into the vitreous body is not as an invasive procedure as the previous two therapies, the agent still raises significant concerns, especially in long-term outcome, because these agents can enter the systemic circulation.16 Intravitreally injected anti-VEGF agents have been found to diminish VEGF serum levels. Ironically, research has concluded that the use of anti-VEGF agents may cause intravitreal angiogenesis, retinal detachment, and continuing avascularized retina.3 In fact, late
reactivation of ROP post-intravitreal anti-VEGF agents has been reported (Table 1).2,17–20

**Oxygen-induced retinopathy animal models**

There are two commonly used OIR animal models: one using mice and the other rats in ROP research. It is noteworthy to remember that unlike humans, these species are born with an incomplete vascularized retina.4 In other words, for them the underdeveloped retinal vasculature is appropriate at birth. Comparison of the phases of OIR in the two models with human ROP stages is necessary. The early phase of human ROP is only reflected in the rat but not the mouse model, and is called phase I or “delayed physiologic retinal vascularization”.4 The vascular phase of stage III ROP with plus disease corresponds to phase II or the IVNV vaso-proliferation phase in both models.4 A few animal models, such as the beagle OIR model, also have a third phase – the fibrovascular phase – that reflects the retinal fibroplasia and eventual detachment characteristics occurring during stages IV and V of human ROP.4 Furthermore, the mouse model demonstrates vaso-obliterration in phase I instead of “delayed physiologic retinal vascularization”.4

**In vivo and in vitro studies: new therapeutic targets**

Aligning with the approach of inhibiting pathological IVNV are studies that target VEGF and related factors like Ang-2 in angiogenesis. Ang-2, a destabilizing factor capable of controlling vessel regression, is expressed by the resting endothelium at low levels under physiologic conditions. However, both VEGF and Ang-2 are strongly upregulated by hypoxia.21 Zhao et al used a compound called calpastatin in attempt to inhibit the degradation of SOCS3, and as a result they were able to eliminate SOCS3, an endogenous inhibitor of the JAK–STAT cascade, drives angiogenesis through both growth factor and cytokine secretion in tumor growth and OIR mice.21 Because of this phenomenon, Miyazaki et al used a compound called calpastatin in attempt to inhibit the degradation of SOCS3, and as a result they were able to suppress pathological angiogenesis. Nevertheless, the mechanism by which calpastatin acted on endothelial cells was not clearly delineated.21 On the other hand, using an inhibitor of VEGFR2 was found to decrease the length and filopodial

---

### Table 1 Conventional treatments for ROP and results from clinical studies

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Trials/studies</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cryosurgery</td>
<td>CRYO-ROP</td>
<td>Cryosurgery-treated eyes have better outcome in terms of letter acuity, grading acuity, and structural outcome of the posterior pole than controls. Results favor long-term efficacy and safety of cryotherapy as a treatment of ROP.17</td>
</tr>
<tr>
<td>Laser photocoagulation</td>
<td>ET-ROP</td>
<td>Early treatment using laser therapy for stage III+ ROP yielded better outcomes. For zone I ROP, laser is only successful in 50% of cases, and can also cause permanent loss of peripheral visual field.2,18</td>
</tr>
<tr>
<td>Anti-VEGF reagents (eg, bevacizumab, ranibizumab)</td>
<td>Retrospective studies</td>
<td>Cautiously used, due to potential adverse outcomes, including a higher incidence of retinal detachment in bevacizumab-treated versus laser therapy-treated eyes2,19 and the occurrence of reactivation of ROP.20</td>
</tr>
</tbody>
</table>

**Abbreviation:** ROP, retinopathy of prematurity.
number of endothelial tip cells. As a result, intraretinal but not intraretinal vascularization is lowered.32

Recall that ROP is associated with fluctuations in oxygen concentrations, the reason being that the fluctuations tend to produce reactive oxygen species.4 Increases in lipid hydroperoxide production have been found in OIR rat retinas.33 Taking advantage of this observation, Saito et al33 tested the effect of antioxidant compound N-acetylcysteine and the NADPH oxidase inhibitor apocynin on IVNV using the 50/10 OIR rat model. Results suggested that apocynin but not N-acetylcysteine could lessen the avascularized area and apoptosis in the retina, possibly involving pathways upstream from lipid hydroperoxide. However, neither had any effect on IVNV.33 In contrast, propranolol, originally used in the treatment of hemangiomas, was reported to be able to inhibit OIR neovascularization based on a mouse study that used nonstandard assessments (fluorescent angiography being unable to detect all neovascular tufts, especially those not fully perfused).13 To reevaluate this finding, Chen et al used a standard evaluation of staining vessels using specific endothelial cell markers to test the effect of propranolol delivered in three different ways—oral gavage, intraperitoneal injection, and subcutaneous injection—on an OIR mouse model. Unfortunately, the latter study proved that neither the doses nor route of delivery of propranolol prevented the development of retinopathy, and higher doses of intraperitoneal injection even intensified pathological vascularization. At the molecular level, propranolol did not alter VEGF expression.13

Cell-based therapy: the next generation of ROP treatment?
Endothelial progenitor cells: early-outgrowth EPCs vs late-outgrowth EPCs
Unlike stem cells (SCs), progenitor cells (PCs) represent a larger variety of cell types, and are thought to be more numerous and more readily accessible. In 1997, Asahara et al identified endothelial PCs (EPCs).34 EPCs were thought to participate in angiogenesis and vasculogenesis.35 Growing evidence also suggests that other PCs are present in distinct organs in the body and contribute to tissue homeostasis, as well as tissue repair and regeneration.36

However, more recently the term “EPCs” has fallen out of use, because it is too vague in nature and actually is inaccurate, as some of these subpopulations do not become endothelial cells. Two types of progenitors—circulating angiogenic cells (CACs; also known as early-outgrowth EPCs or CD34+ cells) and endothelial colony-forming cells (ECFCs; or late-outgrowth EPCs)—differ in their characteristics. CACs originated from the myelomonocytic lineage, and first become noticeable in culture approximately 7 days after isolation. These spindle-shaped cells act mainly as paracrine secretors, are involved in regulation of vascular homeostasis, and initiate vasculogenesis without directly becoming part of the endothelial intima.37,38 Their counterparts, ECFCs, are circulating SCs/PCs that first appear in culture after 10 days of isolation, and can be harvested from umbilical cord blood, bone marrow, or even peripheral blood.39 ECFCs contribute to both angiogenesis and vasculogenesis by integrating directly into the developing vessels.33 They can form tubelike structures in vitro and perfused vessels in vivo if the cells come into contact with perivascular cells like mesenchymal SCs (MSCs).40

Patients with pulmonary arterial hypertension (PAH) have increased numbers of circulating ECFCs in peripheral blood; these ECFCs have been demonstrated to contribute to the vascular remodeling process in PAH.40 Interestingly, using a mouse model of ischemic acute kidney injury, Burger et al showed that human ECFCs, when administered at the time of reperfusion, significantly reduced macrophage infiltration, oxidative stress, and tubular necrosis, even without the cells being retained in the kidneys. Furthermore, exosomes from ECFCs inhibited hypoxia/reoxygenation-induced apoptosis of cocultured human umbilical vein endothelial cells.41

On the other hand, dysfunctional circulating progenitors are implicated in a number of diseases, including but not limited to cardiovascular pathologies, pulmonary hypertension, cancer, and diabetes mellitus.35 Based on the physiologic functions of these cells, it is not surprising to learn that they are able to promote neovascularization in early tumor formation and metastasis. In particular, one study has found that deguelin, a chemopreventive drug, can reduce the number of colony-forming units of bone marrow-derived c-Kit+/Sca-1+ mononuclear cell migration, adhesion, and proliferation capability. When cocultured with endothelial cells, the treated EPC were less likely to form tubelike vessels, because deguelin arrested the cells at the G1 checkpoint.42 In Moyamoya disease (MMD), a form of childhood stroke, the expression of retinaldehyde dehydrogenase 2 is significantly reduced in ECFCs, rendering them less efficient in forming capillary networks in vitro as well as in vivo.43 Teofili et al studied patients with myelodysplastic syndromes, and found that their ECFCs adhered to normal mononuclear cells more strongly compared to those of healthy controls.44 In PAH, ECFCs, located between pulmonary arterial endothelial cells, were found to be more proliferative than healthy ECFCs, and were
proposed to contribute to the proliferative pulmonary vascular remodeling process, the key pathological event of PAH.\textsuperscript{45}

Because of such important roles under both physiologic and pathological conditions, these circulating progenitors have been an appealing topic in the field of vascular biology, and have been considered as the next generation of treatment regimen for ROP.

**Stem/progenitor cells: do they have therapeutic potential in the retina?**

Over the past few decades, studies of therapeutic SCs have become increasingly more popular in several different diseases, such as cardiovascular illnesses and osteonecrosis. SCs can be of embryonic origin or derived from adult organs. Although embryonic SCs possess tremendous potential for differentiation, their use has been restricted due to ethical issues, limited sources, and higher risk of malignant transformation compared to other types of SCs.\textsuperscript{46} Fortunately, various kinds of adult SCs have been studied extensively and used in clinical trials throughout the world.\textsuperscript{47} As of today, the sources of adult SCs include: 1) MSCs derived from bone marrow, human umbilical cord blood, and other tissues, which have been demonstrated to have neuroprotective effects, and may differentiate into other cell types, including neural cells; 2) CACs, which are bone marrow-derived, and provide primarily paracrine support to the vasculature to foster vessel repair; 3) ECFCs, which are isolated from peripheral blood, cord blood, or the stromal vascular fraction, and can form endothelial cells; 4) neural precursor cells, which are multipotent cells found in the developing as well as the adult central nervous system and are heterogeneous, self-renewing, and mitotically active; and 5) induced pluripotent SCs, which can be generated from somatic cells after being treated with a defined cocktail of transcription factors, but tend to be time-consuming and costly.\textsuperscript{47,48}

Research has aimed to use a variety of SC types to study drug delivery or gene therapy.\textsuperscript{47} In a 5-year follow-up study of femoral osteonecrosis in patients with sickle-cell disease, implantation of autologous bone marrow-derived mononuclear cells was reported to relieve pain significantly and slow the progressive early stages of femoral osteonecrosis. Additionally, MSCs from the same patients exhibited physiological characteristics that may have also played a role in the results observed.\textsuperscript{49} Interestingly, patients with osteonecrosis had better improvements on receiving a higher amount of PCs.\textsuperscript{50}

Particularly in the field of vascular biology, evidence has also shown promising therapeutic applications of SCs/PCs and their associated factors. Indeed, in a genetic analysis of hypertensive rats and old mice, gene transfer of the longevity-associated variant \textit{BPIFB4} was able to enhance endothelial nitric oxide synthase and restore endothelial function.\textsuperscript{51} Most importantly, \textit{BPIFB4} is highly expressed in bloodstream CD34\textsuperscript{+} cells in long-living individuals. Moreover, when the \textit{BPIFB4} gene is delivered systemically in a murine model of peripheral ischemia, by recruiting additional hematopoietic SCs, the protein can stimulate reparative vascularization and increase perfusion of the ischemic muscle.\textsuperscript{51} Human placental amniotic SCs (HPASCs) have been shown to exert angiogenic effects on the retina. Kim et al found that systemic injection of these SCs could attenuate proliferation of endothelial cells through their high production of TGF\textbeta\textsubscript{1}, compared to other MSCs. HPASCs injected intraperitoneally in an OIR mouse model actually migrated to the retina to reduce neovascularization, also by secreting TGF\textbeta\textsubscript{1}, and this result was not seen in HPASCs treated with TGF\textbeta\textsubscript{1} small interfering RNA.\textsuperscript{46} Conditioned media from MSC pretreated with treprostinil, a prostacyclin vasodilator indicated for the treatment of PAH, stimulated ECFC proliferation in vitro, and experiments in nude mice further demonstrated that treprostinil-pretreated MSCs also enhanced the vasculogenic properties of ECFCs. All of these effects were attributed to increased production of VEGF-A by treprostinil-pretreated MSCs.\textsuperscript{40} Another type of CAC, called myeloid angiogenic cells and studied by the Stitt Laboratory (Queen’s University Belfast), also promotes angiogenesis in paracrine fashion like CD34\textsuperscript{+} cells. Unlike CD34\textsuperscript{+} cells or ECFCs, myeloid angiogenic cells carry immunophenotypic signatures of M2 macrophages. Nevertheless, they also secrete angiogenic factors, especially IL-8, which promotes VEGF-independent phosphorylation of VEGFR2, and have been shown to reduce the obliterated central area of the retina in the OIR model.\textsuperscript{52}

**Is therapeutic revascularization of the ROP retina by proangiogenic progenitor cells a feasible strategy for the future?**

While current therapies mostly target the IVNV phase of ROP, scientists have become more interested in the early stage or phase I in OIR models. In fact, it has been seen in clinics that infants with zone I ROP are at higher risk of developing severe ROP and have poorer prognosis compared to those with zone II ROP.\textsuperscript{4} Therefore, restoring the vasculature of the immature retina is critical to reducing or preventing IVNV.

Using the OIR mouse model, we have investigated the concept of combination cell therapy for vascular repair. Specifically, we tested exogenous administration of CD34\textsuperscript{+}
cells with ECFCs (Figure 2). Previously, we had shown that healthy CD34+ cells home to areas of ischemia/reperfusion injury in the ROP retina and in the adult diabetic retina.53 Human ECFCs were found to migrate to and be retained for 7 months in nine different vascular networks when they were injected systemically through the tail vein of severe combined immunodeficient mice. The cells did not cause any infarcts or thrombosis.54 Although human ECFCs were also shown to form well-perfused vessels in vivo, they have not been tested in severe combined immunodeficient mice for long-term toxicity studies. Prasain et al examined induced pluripotent SC-derived ECFCs in a model of ROP, and showed that the cells homed to injured areas and corrected ischemia.55

Hypoxic preconditioning (HPC) can further enhance SC/PC function. The rationale rests upon a number of observations. First, bone marrow SCs naturally reside under an oxygen tension of approximately 1%–7%,56,57 and long-term repopulating hematopoietic SCs in the mouse also exist under hypoxic conditions.58 It has been known that when the oxygen level falls below 5%, HIFs will be activated and continue to rise in concentration directly with the decreased level of oxygen.59 In a hypoxic environment, HIF-1α and HIF-2α are protected from ubiquitination and proteasomal degradation, and as a result HIF-1α and HIF-2α concentrations rise, along with other hypoxia-induced messenger RNAs, including those that are important for angiogenesis, apoptosis, and energy metabolism.60–63 In particular, HIF-1α can regulate MSC proliferation by increasing TWIST expression, and consequently downregulates the inhibitory effect of the E2A–p21 pathway on senescence to enhance proliferation.

In addition, HPC causes reduced apoptosis and thereby increases capacity of implanted MSCs in fixing myocardial infarction or diabetic cardiomyopathy. HPC also promotes angiogenesis and vascularization through paracrine factors.64–66 When cultured in a hypoxic environment, human cord blood-derived CD34+ cells can reverse their senescence and become more proliferative again by higher HIF-1α-induced TWIST expression.67 It has been shown that the population-doubling time of marrow-isolated adult multilineage-inducible cells is decreased as oxygen tension is lowered, with the optimal oxygen tension being 3%.68 Therefore, there is ample evidence that preconditioning SCs may improve their viability and function when injected into an adverse and diseased environment, such as ROP or diabetic retina.

**Combination cell therapy**

A combination of ECFCs and CD34+ cells in nude mice was seen to promote revascularization in a synergistic manner in response to acute vascular injury.69 As shown in the schematic in Figure 3, there is considerable evidence to suggest that several SC–PC combinations can serve to enhance vascular repair. There are different populations that can become pericytes or smooth-muscle cells, and these include adipose-derived MSCs (ASC) and bone marrow-derived MSCs.70 ECFCs can serve as a source of endothelial cells, and can easily be combined with either MSC population. As shown in Figure 4, the combined use of CD34+ cells with ECFCs shows improved homing compared to either cell type alone in the ROP model, suggesting that CD34+ cells are likely secreting factors that enhance ECFC function.

Moreover, understanding the molecular factors influencing these cells will likely reveal potential modulators of vascular formation and remodeling. Interestingly, despite the aforementioned important angiogenic property of VEGF, in the absence of IGF-1, VEGF is not sufficient to drive normal development of retinal vasculature. In fact, low levels of IGF-1 are linked to the pathogenesis of ROP.71 However, aberrant expression of IGF-1 can also contribute to pathological neovascularization.72 It is believed that IGF-1 exerts its effects via interactions with IGFBPs. Among these, IGFBP-3 is found to promote
migration of CD34+ cells and differentiation of CD34+ cells to ECs; both are essential for endothelial repair after ischemic injury in the OIR model. The remodeling process occurs through downregulation of CD133 and upregulation of endothelial nitric oxide synthase expression.71 Intriguingly, proliferating ECs that express IGFBP-3 have been shown to be protected from hyperoxia-induced vascular ablation while reducing preretinal neovascularization.73,74 As already stated, restoration of a healthy endothelium not only involves CD34+ cells and ECFCs but also other bone marrow-derived cells, such as pericytes and astrocytes, for their supportive functions. Further investigation reveals that IGFBP-3 indeed enhances differentiation of bone marrow-derived cells into pericytes and astrocytes. Moreover, IGFBP-3 reduces pericyte apoptosis while attenuating activated microglia cells during the hypoxic phase of the OIR model.74

To summarize, angiogenesis is a highly dynamic and finely tuned process that engages both cellular and paracrine factors. By manipulating the right balance of key molecular factors, we will enable the angiogenic cells (i.e., CD34+ cells, ECFCs, and supporting cells like pericytes) to fulfill their functions.

**Conclusion**

ROP continues to be a great concern, particularly in developing countries, where regulating oxygenation of preterm infants is not yet possible. Considering the currently available treatment options for ROP, new innovative approaches for better ROP therapies are definitely needed. More insights are being gained into the pathophysiology of the developing neuronal and vascular retina, and this knowledge will facilitate the translation of basic studies into clinical practice. PCs/SCs have been used therapeutically in other vascular diseases, providing a framework for their study in animal...
models of retinal disease and eventually for their translational to ocular clinical trials. To accelerate the translational process, more preclinical work defining the safety and function of each SC/PC population alone and in combination is needed.

Acknowledgments

This work was supported by the National Institutes of Health (NIH) grants. EY012011, EY007739, HL110170 to MBG, and by a Research to Prevent Blindness unrestricted grant awarded to the Department of Ophthalmology at Indiana University – Purdue University Indianapolis. This paper was presented in part at the Association for Research in Vision and Ophthalmology Annual Meeting in Orlando, FL, May 4–8, 2014, as an oral presentation with interim findings.

Disclosure

The authors report no conflicts of interest in this work.

References

8. Chan-Ling T, Hughes S. NG2 can be used to identify arteries versus veins enabling the characterization of the different functional roles of arterioles and venules within microvascular network growth and remodeling. Microcirculation. 2005;12(7):539–540; author reply 540–541.


